Lantern Pharma Inc. (LTRN)
Company Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.
It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors.
The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways.
Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Country | United States |
IPO Date | Jun 11, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 21 |
CEO | Panna Sharma PH.D. |
Contact Details
Address: 1920 Mckinney Avenue, 7th Floor Dallas, Texas 75201 United States | |
Phone | 972-277-1136 |
Website | lanternpharma.com |
Stock Details
Ticker Symbol | LTRN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $15.00 |
CIK Code | 0001763950 |
CUSIP Number | 51654W101 |
ISIN Number | US51654W1018 |
Employer ID | 46-3973463 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Panna Sharma | President, Chief Executive Officer and Director |
David R. Margrave | Chief Financial Officer and Secretary |
Dr. Kishor Gopaldas Bhatia Ph.D. | Chief Scientific Officer and Scientific Consultant |
Nicole Leber | Investor Relations Associate, Finance and Administrative Coordinator |
Dr. Peter L. Nara D.V.M., M.S., Ph.D. | Co-Founder and Advisor |
Ernest Kitt B.S., M.S | Head of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2024 | 10-K | Annual Report |
Mar 18, 2024 | 8-K | Current Report |
Mar 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Feb 28, 2024 | 144 | Filing |
Feb 28, 2024 | 144 | Filing |
Feb 28, 2024 | 144 | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 29, 2023 | 8-K | Current Report |
Dec 1, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 24, 2023 | 8-K | Current Report |